Tenapanor

CHEMBL3304485 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1145.0 g/mol

LogP

5.1

Phase

4

Tenapanor is a minimally absorbed inhibitor of the intestinal sodium/hydrogen exchanger NHE3 that reduces sodium and phosphate absorption from the gut, approved for irritable bowel syndrome with constipation (IBS-C) and for reduction of serum phosphorus in adults with chronic kidney disease on dialysis. By inhibiting NHE3-mediated paracellular phosphate transport, it significantly lowers serum phosphate levels in dialysis patients. Its local intestinal action with minimal systemic absorption provides a targeted approach with reduced systemic adverse effects.

Peso Molecular

1145,0000 g/mol

LogP

5,10

TPSA

235,00 Å²

Regra dos 5 de Lipinski

Reprovado

Áreas Terapêuticas

Parkinson's Disease Chronic Kidney Disease Type 2 Diabetes

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CN1Cc2c(Cl)cc(Cl)cc2[C@H](c2cccc(S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc([C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc54)c3)c2)C1

InChI

InChI=1S/C50H66Cl4N8O10S2/c1-61-31-43(41-27-37(51)29-47(53)45(41)33-61)35-7-5-9-39(25-35)73(65,66)59-15-19-71-23-21-69-17-13-57-49(63)55-11-3-4-12-56-50(64)58-14-18-70-22-24-72-20-16-60-74(67,68)40-10-6-8-36(26-40)44-32-62(2)34-46-42(44)28-38(52)30-48(46)54/h5-10,25-30,43-44,59-60H,3-4,11-24,31-34H2,1-2H3,(H2,55,57,63)(H2,56,58,64)/t43-,44-/m0/s1

Molecular Formula

C50H66Cl4N8O10S2

HBD / HBA

6 / 14

Ligações Rotacionáveis

29

Átomos Pesados

74

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

Tenapanor is a minimally absorbed inhibitor of the intestinal sodium/hydrogen exchanger NHE3 that reduces sodium and phosphate absorption from the gut, approved for irritable bowel syndrome with constipation (IBS-C) and for reduction of serum phosphorus in adults with chronic kidney disease on dialysis. By inhibiting NHE3-mediated paracellular phosphate transport, it significantly lowers serum phosphate levels in dialysis patients. Its local intestinal action with minimal systemic absorption provides a targeted approach with reduced systemic adverse effects.

Yes, Tenapanor is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3304485. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 71587953. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

Procura informações acessíveis para o paciente?

Tenapanor no PillFYI

Estrutura

Dados Rápidos

Fórmula: C50H66Cl4N8O10S2
Sinônimos: 2

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.